CRISPR Therapeutics AG (CRSP) Change in Accured Expenses (2015 - 2026)

CRISPR Therapeutics AG (CRSP) has 12 years of Change in Accured Expenses data on file, last reported at -$199000.0 in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses fell 100.46% year-over-year to -$199000.0; the trailing twelve-month figure through Mar 2026 stood at $1.7 million (down 89.49% YoY), and the FY2025 full-year result was $44.9 million, up 264.55% from the prior year.
• Change in Accured Expenses retreated to -$199000.0 in Q1 2026, from $4.4 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $43.0 million in Q1 2025 to a low of -$26.9 million in Q4 2024.
• A 5-year average of -$256235.3 and a median of -$432000.0 in 2024 frame the typical range for Change in Accured Expenses.
• Peak annual rise in Change in Accured Expenses reached 16472.73% in 2023, while the deepest fall reached 2304.38% in 2023.
• Tracing CRSP's Change in Accured Expenses over 5 years: stood at $654000.0 in 2022, then plunged by 1505.35% to -$9.2 million in 2023, then plunged by 192.92% to -$26.9 million in 2024, then surged by 116.42% to $4.4 million in 2025, then plunged by 104.5% to -$199000.0 in 2026.
• Business Quant data shows CRSP's Change in Accured Expenses at -$199000.0 in Q1 2026, $4.4 million in Q4 2025, and $12.2 million in Q3 2025.